Quemliclustat not checked

Arcus Biosciences · AB680

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
9 in total · 4 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Non-Small Cell Lung Cancer
Main trialPhase 3
“The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.”In the company’s words, NCT06608927 on ClinicalTrials.gov
Other names
AB680

Other drugs for Metastatic Pancreatic Ductal Adenocarcinoma

All 203 drugs for Metastatic Pancreatic Ductal Adenocarcinoma

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 30 Nov 2030 Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Phase 2Active, not recruiting Dec 2027 Study With Various Immunotherapy Treatments in Participants With Lung Cancer
Phase 2Completed 7 Sep 2026 A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
Phase 1/2Completed 30 Aug 2024 Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Phase 1/2Completed 5 Sep 2025 An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
Phase 1Completed 19 Aug 2019 A Study to Investigate the Safety of AB680 in Healthy Volunteers
Phase 1Completed 22 Sep 2021 A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers
Phase 1Completed 6 Apr 2026 Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)
Phase 1Completed 21 Jul 2026 A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Quemliclustat

Following is part of Solo: you see every change to Quemliclustat the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in